228 related articles for article (PubMed ID: 30768838)
1. Transplanting hepatitis C virus-infected hearts into uninfected recipients: A single-arm trial.
McLean RC; Reese PP; Acker M; Atluri P; Bermudez C; Goldberg LR; Abt PL; Blumberg EA; Van Deerlin VM; Reddy KR; Bloom RD; Hasz R; Suplee L; Sicilia A; Woodards A; Zahid MN; Bar KJ; Porrett P; Levine MH; Hornsby N; Gentile C; Smith J; Goldberg DS
Am J Transplant; 2019 Sep; 19(9):2533-2542. PubMed ID: 30768838
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
Sulkowski M; Hezode C; Gerstoft J; Vierling JM; Mallolas J; Pol S; Kugelmas M; Murillo A; Weis N; Nahass R; Shibolet O; Serfaty L; Bourliere M; DeJesus E; Zuckerman E; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
Lancet; 2015 Mar; 385(9973):1087-97. PubMed ID: 25467560
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial.
Boerekamps A; De Weggheleire A; van den Berk GE; Lauw FN; Claassen MAA; Posthouwer D; Bierman WF; Hullegie SJ; Popping S; van de Vijver DACM; Dofferhoff ASM; Kootstra GJ; Leyten EM; den Hollander J; van Kasteren ME; Soetekouw R; Ammerlaan HSM; Schinkel J; Florence E; Arends JE; Rijnders BJA
Lancet Gastroenterol Hepatol; 2019 Apr; 4(4):269-277. PubMed ID: 30660617
[TBL] [Abstract][Full Text] [Related]
4. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Durand CM; Bowring MG; Brown DM; Chattergoon MA; Massaccesi G; Bair N; Wesson R; Reyad A; Naqvi FF; Ostrander D; Sugarman J; Segev DL; Sulkowski M; Desai NM
Ann Intern Med; 2018 Apr; 168(8):533-540. PubMed ID: 29507971
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
[TBL] [Abstract][Full Text] [Related]
6. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.
Woolley AE; Singh SK; Goldberg HJ; Mallidi HR; Givertz MM; Mehra MR; Coppolino A; Kusztos AE; Johnson ME; Chen K; Haddad EA; Fanikos J; Harrington DP; Camp PC; Baden LR;
N Engl J Med; 2019 Apr; 380(17):1606-1617. PubMed ID: 30946553
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
Lawitz E; Gane E; Pearlman B; Tam E; Ghesquiere W; Guyader D; Alric L; Bronowicki JP; Lester L; Sievert W; Ghalib R; Balart L; Sund F; Lagging M; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
Lancet; 2015 Mar; 385(9973):1075-86. PubMed ID: 25467591
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients.
Gane E; Nahass R; Luketic V; Asante-Appiah E; Hwang P; Robertson M; Wahl J; Barr E; Haber B
J Viral Hepat; 2017 Oct; 24(10):895-899. PubMed ID: 28470815
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
Kwo P; Gane EJ; Peng CY; Pearlman B; Vierling JM; Serfaty L; Buti M; Shafran S; Stryszak P; Lin L; Gress J; Black S; Dutko FJ; Robertson M; Wahl J; Lupinacci L; Barr E; Haber B
Gastroenterology; 2017 Jan; 152(1):164-175.e4. PubMed ID: 27720838
[TBL] [Abstract][Full Text] [Related]
10. High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.
Braun DL; Hampel B; Kouyos R; Nguyen H; Shah C; Flepp M; Stöckle M; Conen A; Béguelin C; Künzler-Heule P; Nicca D; Schmid P; Delaloye J; Rougemont M; Bernasconi E; Rauch A; Günthard HF; Böni J; Fehr JS;
Clin Infect Dis; 2019 Feb; 68(4):569-576. PubMed ID: 30107485
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
Asselah T; Reesink H; Gerstoft J; de Ledinghen V; Pockros PJ; Robertson M; Hwang P; Asante-Appiah E; Wahl J; Nguyen BY; Barr E; Talwani R; Serfaty L
Liver Int; 2018 Sep; 38(9):1583-1591. PubMed ID: 29461687
[TBL] [Abstract][Full Text] [Related]
12. Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.
Lawitz E; Poordad F; Gutierrez JA; Wells JT; Landaverde CE; Evans B; Howe A; Huang HC; Li JJ; Hwang P; Dutko FJ; Robertson M; Wahl J; Barr E; Haber B
Hepatology; 2017 Feb; 65(2):439-450. PubMed ID: 27770561
[TBL] [Abstract][Full Text] [Related]
13. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study.
Feld JJ; Cypel M; Kumar D; Dahari H; Pinto Ribeiro RV; Marks N; Kamkar N; Bahinskaya I; Onofrio FQ; Zahoor MA; Cerrochi O; Tinckam K; Kim SJ; Schiff J; Reichman TW; McDonald M; Alba C; Waddell TK; Sapisochin G; Selzner M; Keshavjee S; Janssen HLA; Hansen BE; Singer LG; Humar A
Lancet Gastroenterol Hepatol; 2020 Jul; 5(7):649-657. PubMed ID: 32389183
[TBL] [Abstract][Full Text] [Related]
14. Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study.
Bethea ED; Gaj K; Gustafson JL; Axtell A; Lebeis T; Schoenike M; Turvey K; Coglianese E; Thomas S; Newton-Cheh C; Ibrahim N; Carlson W; Ho JE; Shah R; Nayor M; Gift T; Shao S; Dugal A; Markmann J; Elias N; Yeh H; Andersson K; Pratt D; Bhan I; Safa K; Fishman J; Kotton C; Myoung P; Villavicencio MA; D'Alessandro D; Chung RT; Lewis GD
Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):771-780. PubMed ID: 31353243
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
Rockstroh JK; Nelson M; Katlama C; Lalezari J; Mallolas J; Bloch M; Matthews GV; Saag MS; Zamor PJ; Orkin C; Gress J; Klopfer S; Shaughnessy M; Wahl J; Nguyen BY; Barr E; Platt HL; Robertson MN; Sulkowski M
Lancet HIV; 2015 Aug; 2(8):e319-27. PubMed ID: 26423374
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis.
Asselah T; Zeuzem S; Reau N; Hwang P; Long J; Talwani R; Robertson MN; Haber BA
Curr Med Res Opin; 2020 Aug; 36(8):1325-1332. PubMed ID: 32459122
[No Abstract] [Full Text] [Related]
17. Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3.
Yeh WW; Fraser IP; Jumes P; Petry A; Lepeleire I; Robberechts M; Reitmann C; Van Dyck K; Huang X; Guo Z; Panebianco D; Nachbar RB; O'Mara E; Wagner JA; Butterton JR; Dutko FJ; Moiseev V; Kobalava Z; Hüser A; Visan S; Schwabe C; Gane E; Popa S; Ghicavii N; Uhle M; Wagner F
Clin Ther; 2018 May; 40(5):704-718.e6. PubMed ID: 29703432
[TBL] [Abstract][Full Text] [Related]
18. Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient.
Chen J; Li Y; Li G; Lei P
Ren Fail; 2020 Nov; 42(1):377-380. PubMed ID: 32301365
[TBL] [Abstract][Full Text] [Related]
19. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.
Zeuzem S; Serfaty L; Vierling J; Cheng W; George J; Sperl J; Strasser S; Kumada H; Hwang P; Robertson M; Wahl J; Barr E; Talwani R; Platt H
J Gastroenterol; 2018 May; 53(5):679-688. PubMed ID: 29344726
[TBL] [Abstract][Full Text] [Related]
20. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
Sise ME; Goldberg DS; Kort JJ; Schaubel DE; Alloway RR; Durand CM; Fontana RJ; Brown RS; Friedewald JJ; Prenner S; Landis JR; Fernando M; Phillips CC; Woodle ES; Rike-Shields A; Sherman KE; Elias N; Williams WW; Gustafson JL; Desai NM; Barnaba B; Norman SP; Doshi M; Sultan ST; Aull MJ; Levitsky J; Belshe DS; Chung RT; Reese PP
J Am Soc Nephrol; 2020 Nov; 31(11):2678-2687. PubMed ID: 32843477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
